



Mechanism by which arylamine N-acetyltransferase 1 ablation causes insulin resistance in mice

Camporez, João Paulo; Wang, Yongliang; Faarkrog, Kasper; Chukijrunroat, Natsasi; Petersen, Kitt Falk; Shulman, Gerald I.

Published in:

Proceedings of the National Academy of Sciences of the United States of America

DOI:

[10.1073/pnas.1716990115](https://doi.org/10.1073/pnas.1716990115)

Publication date:

2017

Document version

Publisher's PDF, also known as Version of record

Document license:

[CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Citation for published version (APA):

Camporez, J. P., Wang, Y., Faarkrog, K., Chukijrunroat, N., Petersen, K. F., & Shulman, G. I. (2017). Mechanism by which arylamine N-acetyltransferase 1 ablation causes insulin resistance in mice. *Proceedings of the National Academy of Sciences of the United States of America*, 114(52), E11285-E11292. <https://doi.org/10.1073/pnas.1716990115>

Mechanism by which arylamine *N*-acetyltransferase 1 ablation causes insulin resistance in mice

João Paulo Camporez^{a,1}, Yongliang Wang^{a,1}, Kasper Faarkrog^{a,b}, Natsasi Chukijrungrat^a, Kitt Falk Petersen^{a,b}, and Gerald I. Shulman^{a,b,c,d,2}

^aDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520; ^bNovo Nordisk Center for Basic Metabolic Research, University of Copenhagen, Copenhagen DK-2200, Denmark; ^cDepartment of Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520; and ^dHoward Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520

Contributed by Gerald I. Shulman, November 15, 2017 (sent for review October 3, 2017; reviewed by Joshua W. Knowles and Carsten Schmitz-Peiffer)

A single-nucleotide polymorphism in the human arylamine *N*-acetyltransferase 2 (*Nat2*) gene has recently been identified as associated with insulin resistance in humans. To understand the cellular and molecular mechanisms by which alterations in *Nat2* activity might cause insulin resistance, we examined murine ortholog *Nat1* knockout (KO) mice. *Nat1* KO mice manifested whole-body insulin resistance, which could be attributed to reduced muscle, liver, and adipose tissue insulin sensitivity. Hepatic and muscle insulin resistance were associated with marked increases in both liver and muscle triglyceride (TAG) and diacylglycerol (DAG) content, which was associated with increased PKC ϵ activation in liver and increased PKC θ activation in skeletal muscle. *Nat1* KO mice also displayed reduced whole-body energy expenditure and reduced mitochondrial oxygen consumption in white adipose tissue, brown adipose tissue, and hepatocytes. Taken together, these studies demonstrate that *Nat1* deletion promotes reduced mitochondrial activity and is associated with ectopic lipid-induced insulin resistance. These results provide a potential genetic link among mitochondrial dysfunction with increased ectopic lipid deposition, insulin resistance, and type 2 diabetes.

mitochondria | diacylglycerol | protein kinase ϵ | protein kinase θ | ceramides

Insulin resistance in liver and skeletal muscle is a major factor in the pathogenesis of type 2 diabetes; however, the molecular mechanism or mechanisms responsible for this phenomenon have not been established. In this context, several cellular mechanisms have been proposed to be responsible for insulin resistance in these tissues, including alterations in circulating adipocytokines resulting from inflammation (1, 2), increased endoplasmic reticulum stress (3, 4), and increases in ectopic lipid [diacylglycerol (DAG) (5–9) and ceramide (10–12)] content.

Recently, a genome-wide association study found an association with a single-nucleotide polymorphism in the human *N*-acetyltransferase 2 (*Nat2*) gene associated with insulin resistance in humans (13). This study also found that knockdown of *Nat1* caused insulin resistance in murine 3T3-L1 adipocytes and that *Nat1* (the murine ortholog of *Nat2*) knockout (KO) mice displayed decreased glucose tolerance, suggesting whole-body insulin resistance (13). Nevertheless, the mechanisms by which alterations in the *Nat1* gene might cause insulin resistance is unknown. To address this question, we performed comprehensive metabolic analyses of regular chow (RC)-fed and high-fat diet (HFD)-fed *Nat1* KO mice. Specifically, we examined basal and insulin-stimulated rates of liver, muscle, and white adipose tissue (WAT) glucose metabolism assessed during a hyperinsulinemic-euglycemic clamp combined with [³-³H]glucose, [²H₅]glycerol, and [¹³C₁₆]palmitate infusions. These measurements were combined with assessment of whole-body energy expenditure, activity, food intake, and ¹H NMR assessment of lean body and fat mass along with liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of liver and muscle lipid

intermediates (DAGs, ceramides) that have been implicated in causing insulin resistance in liver and skeletal muscle.

Results

***Nat1* Deficiency Causes Whole-Body Insulin Resistance.** The WT and *Nat1* KO mice were studied at 12 wk of age and displayed no differences in body weight or body fat between groups when fed either RC or a HFD for 4 wk (Table 1).

To evaluate whether the *Nat1* deficiency would cause insulin resistance and, if so, to determine which tissues were responsible for the insulin resistance, we performed hyperinsulinemic-euglycemic clamp studies combined with radiolabeled glucose in *Nat1* KO and WT littermate mice. The deficiency of *Nat1* in RC-fed mice caused whole-body insulin resistance, reflected by a marked reduction in the glucose infusion rate required to maintain euglycemia during the hyperinsulinemic-euglycemic clamp (Fig. 1A). This difference in glucose infusion rate was partially accounted for by reduction in peripheral insulin sensitivity in the *Nat1* KO mice. The *Nat1* KO mice displayed reduced insulin-stimulated muscle and WAT glucose uptake, as well as reduced insulin-stimulated whole-body glucose turnover (Fig. 1B and C). *Nat1* KO mice also manifested hepatic insulin resistance, as reflected by reduced insulin-stimulated suppression of endogenous glucose production during the clamp (Fig. 1D). Although it has been shown that *Nat1* deficiency in vitro induced increased lipolysis

Significance

Insulin resistance in liver and skeletal muscle are major factors in the pathogenesis of type 2 diabetes; however, the molecular mechanism or mechanisms responsible for this phenomenon have not been established. Recently, an association of a single-nucleotide polymorphism in the human *N*-acetyltransferase 2 (*Nat2*) gene with insulin resistance in humans was found. Here, we show that the murine ortholog *Nat1* knockout (KO) mice manifested whole-body insulin resistance associated with marked increases in liver and muscle lipid content. *Nat1* KO mice also displayed reduced whole-body energy expenditure and reduced mitochondrial activity. Taken together, these studies demonstrate that *Nat1* deletion promotes reduced mitochondrial activity and is associated with ectopic lipid-induced liver and muscle insulin resistance.

Author contributions: J.P.C., K.F.P., and G.I.S. designed research; J.P.C., Y.W., K.F., N.C., and K.F.P. performed research; J.P.C., Y.W., K.F., K.F.P., and G.I.S. analyzed data; and J.P.C., K.F.P., and G.I.S. wrote the paper.

Reviewers: J.W.K., Stanford University School of Medicine; and C.S.-P., Garvan Institute of Medical Research.

The authors declare no conflict of interest.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

¹J.P.C. and Y.W. contributed equally to this work.

²To whom correspondence should be addressed. Email: gerald.shulman@yale.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716990115/-DCSupplemental.

Table 1. General parameters from WT and Nat1 KO mice fed either RC or a HFD at 12 wk of age

Parameters	WT	KO
Body weight (RC), g	27.5 ± 0.4	27.6 ± 0.5
Body fat (RC), g	1.7 ± 0.1	2.0 ± 0.2
Body weight (HFD), g	34.2 ± 1.3	36.5 ± 0.9
Body fat (HFD), g	7.9 ± 0.8	9.9 ± 0.8
Fasting insulin (RC), μU/mL	5.4 ± 0.7	6.9 ± 0.8
Clamped insulin (RC), μU/mL	34.9 ± 2.6	35.9 ± 1.8
Fasting Insulin (HFD), μU/mL	14.0 ± 3.3	37.4 ± 8.5*
Clamp insulin (HFD), μU/mL	97.3 ± 5.2	110.5 ± 10.3
Basal NEFA (RC), mmol/L	1.14 ± 0.07	1.12 ± 0.08
Clamp NEFA (RC), mmol/L	0.34 ± 0.03	0.39 ± 0.02
Basal NEFA (HFD), mmol/L	1.18 ± 0.07	1.15 ± 0.05
Clamp NEFA (HFD), mmol/L	0.70 ± 0.05	1.11 ± 0.05**
Plasma TAG (RC), mg/dL	94.5 ± 4.6	99.8 ± 5.9
Plasma TAG (HFD), mg/dL	92.3 ± 3.7	91.1 ± 5.0
Plasma FGF21 (RC), pg/mL	423.2 ± 61.9	540.1 ± 80.8

Data are represented as mean ± SEM ($n = 8-10$ per group).

* $P < 0.05$.

** $P < 0.001$ compared with WT mice fed the same diet.

in 3T3-L1 adipocytes (13), Nat1 KO mice fed RC did not display any alteration in WAT lipolysis measured in vivo, evaluated by nonesterified fatty acid (NEFA) levels (Table 1), palmitate turnover, and glycerol turnover (Fig. 1 E and F).

Next, to determine whether Nat1 KO mice would be more prone to HFD-induced insulin resistance, the rodents were fed a HFD for 4 wk before the hyperinsulinemic-euglycemic clamp was performed. Nat1 deficiency induced severe whole-body insulin resistance, observed by a reduction in the glucose infusion rate required to maintain euglycemia during the clamp (Fig. 1G) compared with WT mice. This reduction in glucose infusion rate was accounted for by reduced whole-body glucose turnover during the clamp (Fig. 1H), and consequently, reduction in insulin-stimulated muscle and WAT glucose uptake (Fig. 1I), as well as severe hepatic insulin resistance, as reflected by the lack of suppression in endogenous glucose production during the clamp (Fig. 1J) and a severe defect in insulin-stimulated suppression in WAT lipolysis (Fig. 1 K and L).

Nat1 Deficiency Leads to Ectopic Lipid Accumulation in Liver and Muscle and Reduced Insulin Signaling in Liver and Skeletal Muscle.

Given the strong causal relationship between ectopic lipid accumulation and hepatic and muscle insulin resistance shown in previous studies (4, 14–16), we measured DAG and ceramide content as well as translocation (activation) of PKC ϵ in liver and PKC θ in skeletal muscle in RC and HFD rodents. Hepatic TAG, DAG, and ceramides were increased in KO mice in either the RC or HFD condition (Fig. 2 A–C and Tables S1 and S3). Consistent with increased DAG content in liver, Nat1 KO mice fed either RC or a HFD displayed increased PKC ϵ activation (Fig. 2D), suggesting the increased hepatic DAG content led to hepatic insulin resistance through activation of PKC ϵ , as previously demonstrated (5, 17–19).

Ectopic lipid content was also evaluated in skeletal muscle. TAG and DAG content were increased in muscle from Nat1 KO mice fed either RC or a HFD (Fig. 2 E and F and Tables S2 and S4). In contrast to what was observed in liver, ceramide content was not increased in skeletal muscle from RC-fed mice, despite the presence of muscle insulin resistance (Fig. 2G). Nat1 KO mice fed a HFD displayed increased muscle DAG (Fig. 2F) and ceramide content (Fig. 2G), and the increased DAG content in muscle was associated with increased PKC θ activation (Fig. 2H).

Increased DAG content in liver and skeletal muscle has been shown to play a causal role in liver and muscle insulin resistance

by activation of PKC ϵ in liver and PKC θ in skeletal muscle, leading to inhibition of insulin signaling at the level of the insulin receptor kinase (IRK) in liver (17–19) and at the level of insulin receptor substrate 1 tyrosine phosphorylation in skeletal muscle (5, 6, 8, 9). Consistent with this hypothesis, increased DAG content in liver in Nat1 KO mice was associated with reduced insulin-stimulated IRK tyrosine phosphorylation and Akt phosphorylation in liver (Fig. 2 I–K), which provides further support of recent studies demonstrating that DAG activation of PKC ϵ in liver promotes increased phosphorylation of a critical threonine (threonine¹¹⁶⁰ human IRK, threonine¹¹⁵⁰ mouse IRK) in the catalytic subunit of the IRK leading to decreased IRK tyrosine phosphorylation and reduced IRK activity (19). Consistent with DAG activation of PKC θ inhibiting insulin signaling downstream of the IRK, Nat1 KO mice displayed reduced insulin-stimulated Akt phosphorylation in skeletal muscle without any changes in IRK tyrosine phosphorylation (9) (Fig. 2 L–N).

Nat1 Deficiency Was Associated with Decreased Energy Expenditure and Mitochondrial Dysfunction.

Previous studies in humans have found a strong relationship between increased ectopic lipid content in liver and skeletal muscle and insulin resistance, and hypothesized that reduced mitochondrial activity in these organs may be a predisposing factor for increased ectopic lipid accumulation and insulin resistance in these organs (20–23). To evaluate whether whole-body oxygen consumption and energy expenditure were altered in these Nat1 KO mice, these parameters were assessed by metabolic cages. Whole-body oxygen consumption, carbon dioxide production, and energy expenditure were reduced in Nat1 KO mice fed RC compared with WT mice (Fig. 3 A–C), without any difference between groups regarding quotient respiratory, caloric intake, drinking, and activity (Fig. 3 D–G). These effects were also observed in Nat1 KO mice fed HFD, displaying reduced whole-body oxygen consumption, carbon dioxide production, and energy expenditure (Fig. 3 H–J). In contrast, there was no difference among groups regarding quotient respiratory, caloric intake, drinking, and activity (Fig. 3 K–N).

We also performed an evaluation of oxygen consumption in hepatocytes, WAT, and brown adipose tissue (BAT) isolated from Nat1 KO and WT mice by Seahorse analyses to determine whether these tissues were contributing to the reduced whole-body energy expenditure in the Nat1 KO mice. In vitro oxygen consumption in WAT and BAT were reduced in Nat1 KO mice compared with WT mice (Fig. 4 A–C). Hepatocytes from Nat1 KO mice also displayed reduced oxygen consumption in vitro compared with WT mice (Fig. 4 D and E).

Discussion

A single-nucleotide polymorphism in the human Nat2 gene has recently been identified to be associated with insulin resistance in humans. However, the mechanism by which alterations in the Nat2 gene might cause insulin resistance is unknown. To address this question, we performed a comprehensive metabolic analysis of murine ortholog Nat1 KO mice fed either RC or a HFD. Specifically, we examined basal and insulin-stimulated rates of liver, muscle, and WAT glucose metabolism assessed by a hyperinsulinemic-euglycemic clamp study. These measurements were combined with assessment of whole-body energy expenditure, activity, food intake, and ¹H NMR measurements of lean body and fat mass, as well as LC-MS/MS analyses of liver and muscle lipid intermediates (ceramides, DAGs), which have been implicated as causal factors in liver and muscle insulin resistance. Using this approach, we find that Nat1 KO mice displayed whole-body insulin resistance on a RC diet, with reduced insulin-stimulated glucose uptake in skeletal muscle and reduced insulin-stimulated suppression of endogenous glucose production during a hyperinsulinemic-euglycemic clamp. Interestingly, insulin resistance in liver and skeletal muscle was further exacerbated when the Nat1 KO mice




Fig. 1. Nat1 KO mice display insulin resistance in liver, muscle, and WAT, which was exacerbated by HFD. Time-course of plasma glucose and glucose infusion rates (GIR) (A) during the hyperinsulinemic-euglycemic clamp of WT and Nat1 KO mice fed RC. (B) Whole-body insulin-stimulated glucose uptake. (C) Insulin-stimulated skeletal muscle and WAT 2-deoxy-glucose uptake. (D) Basal and clamp endogenous glucose production. (E) Basal and clamp palmitate turnover. (F) Basal and clamp glycerol turnover. (G) Time-course of plasma glucose and GIR during the hyperinsulinemic-euglycemic clamp of WT and Nat1 KO mice fed a HFD. (H) Whole-body insulin-stimulated glucose uptake. (I) Insulin-stimulated skeletal muscle and WAT 2-deoxy-glucose uptake. (J) Basal and clamp endogenous glucose production. (K) Basal and clamp palmitate turnover. (L) Basal and clamp glycerol turnover. Data are represented as mean \pm SEM ($n = 10$ per group).





Fig. 2. Nat1 KO mice display increased ectopic lipid content and reduced insulin signaling in liver and skeletal muscle. Hepatic TAG (A), hepatic membrane DAG (B), and hepatic ceramides (C) content in WT and KO mice fed either RC or a HFD. Hepatic PKC ϵ activation (D) in WT and KO mice fed either RC or a HFD. Muscle TAG (E), muscle membrane DAG (F), and muscle ceramides (G) content in WT and KO mice fed either RC or a HFD. Muscle PKC θ activation (H) in WT and KO mice fed either RC or a HFD. Western blot images and quantification for insulin-stimulated IRK phosphorylation pY1158 (I) and pY1162 (J), and Akt phosphorylation (K) in liver. Western blot images and quantification for insulin-stimulated IRK phosphorylation pY1158 (L) and pY1162 (M) and Akt phosphorylation (N) in muscle. Data are represented as mean \pm SEM ($n = 8-12$ per group).

Regular Chow Fed Mice



High Fat Diet Fed Mice




Fig. 3. Nat1 KO mice display reduced whole-body energy expenditure. Whole-body oxygen consumption (A), carbon dioxide production (B), energy expenditure (C), respiratory exchange ratio (D), caloric intake (E), drinking (F), and daily activity (G) in WT and KO mice fed RC. Whole-body oxygen consumption (H), carbon dioxide production (I), energy expenditure (J), respiratory exchange ratio (K), caloric intake (L), drinking (M), and daily activity (N) in WT and KO mice fed a HFD. Data are represented as mean \pm SEM ($n = 10$ per group).

were fed a HFD. In addition to the reduced insulin-stimulated muscle glucose uptake and decreased suppression of hepatic glucose production, Nat1 KO mice also displayed reduced insulin-stimulated suppression of WAT lipolysis, which may have contributed to the severe metabolic phenotype in these mice (24).

Ectopic lipid deposition in liver and skeletal muscle has been shown to be strongly associated with insulin resistance in liver and muscle (9, 25, 26), and increases in DAGs (4, 6, 7, 9, 14, 27) and ceramides (10–12) have both been implicated at the molecular

triggers in this process. Increased DAG content in liver has been shown to promote increase PKC ϵ translocation to the plasma membrane, which in turn has been shown to phosphorylate threonine¹¹⁶⁰ (threonine¹¹⁵⁰ mouse) in the IRK catalytic domain, leading to inhibition of IRK activity (17–19). In contrast, increases in muscle DAG content have been shown to increase PKC θ translocation, leading to decreased insulin signaling at the level of IRS-1 tyrosine phosphorylation (28–30). These findings have recently been translated to humans, in that increased DAG content and PKC ϵ




Fig. 4. Nat1 KO mice have lower tissue oxygen consumption. Oxygen consumption rates (OCR) measured in gonadal fat (A), inguinal fat (B), BAT (C), and isolated primary hepatocytes (D and E) from WT and KO mice. Data are represented as mean \pm SEM ($n = 5$ per group).

translocation have been shown to be strongly associated with hepatic insulin resistance in obese individuals undergoing bariatric surgery (31, 32), and increased DAG content and PKC θ translocation were found to be strongly associated with muscle insulin resistance in obese subjects and patients with type 2 diabetes (33). Consistent with this mechanism, we observed an increase in liver and muscle DAG content in Nat1 KO mice that was associated with an increase in PKC ϵ and PKC θ in liver and muscle, respectively. In contrast, we saw only small increases in hepatic ceramide content in Nat1 KO mice and no increase in muscle ceramide content in Nat1 KO mice, despite the presence of muscle insulin resistance.

To further understand the underlying mechanism responsible for the increased ectopic lipid content in Nat1 KO mice, we performed comprehensive metabolic cage studies for 4 consecutive days to evaluate energy expenditure and feeding behavior. We observed that the Nat1 KO mice displayed reduced whole-body energy expenditure. Taken together, these data suggest that decreased energy expenditure may be responsible for the increased hepatic and muscle ectopic lipid accumulation and insulin resistance in Nat1 KO mice. Furthermore, these results are consistent with prior studies demonstrating that decreased energy expenditure in rodents leads to reduced insulin sensitivity associated with increased ectopic lipid content (15), and that increased energy expenditure resulting from increased mitochondrial activity in liver and/or skeletal muscle (27, 28, 34, 35) can protect mice from HFD-induced insulin resistance in liver and skeletal muscle.

To understand which tissues might be responsible for the reduced whole-body energy expenditure in Nat1 KO mice, we assessed in vitro oxygen consumption in WAT, BAT, and primary hepatocytes obtained from Nat1 KO and age- and weight-matched littermate WT mice. Using this approach, we found that oxygen consumption was markedly reduced in all these tissues, suggesting Nat1 deficiency may lead to global reductions in mitochondrial activity in all tissues. Indeed, it was recently shown that Nat1 KO mice display mitochondrial dysfunction (36), corroborating our data. This manuscript showed that mitochondria from Nat1 KO mice displayed increased superoxide production and reduction in PGC-1 α expression, as well as mitochondrial genes (such as Nrf1, Tfam, Cyscs, and Atp5). These alterations resulted in reduced mitochondria oxygen consumption, reduced whole-body energy expenditure, and reduced exercise tolerance. The authors in this study performed the in vivo experiments in 16-wk-old mice, which resulted in differences in body weight between groups. Knowing that differences in body weight can profoundly affect the analysis of whole-body energy metabolism (37), we extended these findings of in vivo energy metabolism in Nat1 KO mice by performing all the experiments in body weight-matched mice (12-wk-old mice) and examining these same parameters in HFD-fed Nat1 KO mice. Moreover, most of the in vitro oxygen measurement data by Chennamsetty et al. (36) were collected from immortalized cell lines with knock-down of Nat1 protein. Here, we expanded and corroborated these findings by measuring oxygen consumption in WAT and BAT as

well as primary hepatocytes from WT and Nat1 KO mice, showing that all these tissues displayed reduced oxygen consumption.

Insulin resistance associated with mitochondrial dysfunction is a notable finding, as this relationship has been described in rodents (27, 38, 39), as well as in humans (20–23), where reductions in mitochondrial oxidative-phosphorylation activity assessed by *in vivo* NMR spectroscopy was found to be associated with increased ectopic lipid content and insulin resistance in muscle of lean healthy elderly people and insulin-resistant offspring of patients with type 2 diabetes who are prone to develop diabetes later in life (20–23, 40). The results complement previous studies demonstrating a key role for alterations in mitochondrial dysfunction in the pathogenesis of insulin resistance, which found that aging-associated reduction in mitochondrial activity and aging-associated ectopic lipid (DAG-novel PKC)-induced insulin resistance in liver and skeletal muscle can be prevented by targeting catalase to the mitochondria (27).

In summary, these data demonstrate that deletion of the Nat1 gene in mice caused reduced mitochondrial activity, which resulted in decreased whole-body energy expenditure and increased ectopic lipid accumulation in liver and skeletal muscle. Increased DAG content in liver and skeletal muscle was associated with increased PKC ϵ (liver) and PKC θ (muscle) activity and insulin resistance in liver and skeletal muscle when mice were fed a RC diet. These effects were further exacerbated when Nat1 KO mice were challenged with a HFD.

These data provide insights into how variants in the Nat2 gene may predispose humans to insulin resistance and type 2 diabetes and provide a potential genetic link between mitochondrial dysfunction with increased ectopic lipid deposition and insulin resistance.

Methods

Animal Procedures. Nat1 KO mice were obtained from Jackson Labs. Mice were then generated for experiments breeding heterozygous \times heterozygous mice to obtain WT and KO littermates mice. The animals were individually housed under controlled temperature (23 °C) and lighting (12:12 h light/dark cycle, lights on at 7:00 AM) conditions, with free access to water and food. Mice were fed either RC or a HFD (D12492; Research Diets) for 4 wk. Body composition was assessed by ^1H magnetic resonance spectroscopy, using a Bruker Minispec analyzer (Bruker BioSpin). All experimental procedures were approved by and conducted in accordance with the Institutional Animal Care and Use Committee guidelines of Yale University School of Medicine.

Hyperinsulinemic-Euglycemic Clamp Studies. Hyperinsulinemic-euglycemic clamps were performed as previously described (6). Briefly, a catheter was implanted in the jugular vein 7 d before the experiments. After overnight fasting, conscious mice were infused with [^3H]-glucose (HPLC purified; Perkin-Elmer Life Sciences) at a rate of 0.05 $\mu\text{Ci}/\text{min}$ for 120 min for basal glucose turnover measurement. After the basal infusion, hyperinsulinemic-euglycemic clamps were conducted for 140 min with a 3-min primed infusion of insulin [6.0 mU/(kg·min)] and [^3H]-glucose (0.24 $\mu\text{Ci}/\text{min}$), followed by a continuous infusion of insulin [2.5 mU/(kg·min)] and [^3H]-glucose (0.1 $\mu\text{Ci}/\text{min}$), and a variable infusion of 20% dextrose to maintain euglycemia (~120 mg/dL). After 85 min, a bolus of 2-deoxy-d-[1- ^{14}C]glucose (PerkinElmer) (10 μCi) was injected to evaluate insulin-stimulated tissue glucose uptake. At the end of the clamps, mice were anesthetized with a sodium pentobarbital injection (150 mg/kg), and liver, WAT, and skeletal muscle (gastrocnemius + soleus) were taken and snap-frozen in liquid nitrogen and stored at $-80\text{ }^\circ\text{C}$ for subsequent analyses.

Comprehensive Animal Metabolic Monitoring System. Comprehensive animal metabolic monitoring system (Columbus Instruments) was used to evaluate

O_2 consumption, CO_2 production, energy expenditure, activity, and food consumption. Drinking was assessed by a computer system counting consumed water droplets.

Lipid Measurements. Tissue TAGs were extracted using the method of Folch et al. (41) and measured using a DCL TAG reagent (Diagnostic Chemicals). For DAG extraction, livers and muscles were homogenized in a buffer solution (20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 0.25 mM EGTA, 250 mM sucrose) containing a protease inhibitor mixture (Roche), and samples were centrifuged at $100,000 \times g$ for 1 h. The supernatants containing the cytosolic fraction and the pellet containing the membrane fraction were collected. DAG and ceramide concentrations were measured by LC-MS/MS, as previously described (30). Total cytosolic and membrane DAG and ceramide content are expressed as the sum of individual species. All lipid measurements were made from tissues harvested from 6-h fasted mice.

Oxygen Consumption Measurements. Primary hepatocytes from WT and KO mice were isolated at the Yale Liver Center. Cells were washed three times with recovery media (DMEM with high glucose plus 10% FBS), and an equal amount of cells (12,000) was seeded in each well of a Seahorse XF24 cell culture plate (Seahorse Bioscience). These experiments were repeated six times under the same conditions as previously described (14). Briefly, cells were kept in recovery media for 4–6 h and then washed with DMEM media (low glucose plus 10% FBS) and incubated overnight. The following morning, cells were washed with prewarmed ($\sim 37\text{ }^\circ\text{C}$) XF24 Assay media. XF24 Assay media (525 μL) was then added to each well. Immediately before measurements, cells with assay media were placed in an unbuffered, humidified incubator at $37\text{ }^\circ\text{C}$ for 1 h to allow temperature and pH equilibration. Three measurements of oxygen consumption rate were taken, and the average of three measurements was used for analysis. These experiments were repeated six times using six different mice per group under the same conditions.

In addition, freshly isolated mouse gonadal or inguinal s.c. WAT or BAT were rinsed with XF-DMEM (containing 25 mM Hepes) and cut into small pieces (~ 10 mg). After extensive washing, one piece of tissue was placed in each well of a XF24 Islet Capture Microplate (Seahorse Bioscience) and covered with the islet capture screen that allows free perfusion while minimizing tissue movement. XF Assay Medium (500 μL) was added, and samples were analyzed in the XF24 Analyzer.

Immunoblot Analysis. Tissues were homogenized in RIPA lysis buffer supplemented with protease inhibitor mixture (Roche) for protein isolation. Proteins from homogenized liver or skeletal muscle (100 μg protein extracts) were electrophoretically separated by 4–12% SDS/PAGE (Invitrogen) and then transferred to polyvinylidene difluoride membranes (Millipore), using a semidry transfer cell (Bio-Rad) for 120 min. After blockade of nonspecific sites with 5% nonfat dry milk TBST (10 mM Tris, 100 mM NaCl, 0.1% Tween 20) solution, membranes were incubated overnight at $4\text{ }^\circ\text{C}$ with the following primary antibodies: total IRK, tyrosine pY1158 IRK, tyrosine pY1162 IRK, total Akt, and Akt phosphorylation Ser 473 (Santa Cruz Biotechnology, Inc.), PKC ϵ (BD Transduction Laboratories), PKC θ (BD Transduction Laboratories), or GAPDH (Santa Cruz Biotechnology, Inc.). After washing with TBST, membranes were incubated with peroxidase-conjugated anti-rabbit, or anti-mouse. Membranes were thoroughly washed, and immune complexes were detected using an enhanced luminol chemiluminescence system (Thermo Scientific) and subjected to photographic films. Signals on the immunoblot were quantified by optical densitometry (Scion Image Software).

Statistics. All data are expressed as mean \pm SEM. Results were assessed using two-tailed unpaired Student's *t* test or two-way ANOVA (GraphPad Prism 5). A *P* value less than 0.05 was considered significant.

ACKNOWLEDGMENTS. We thank Ali Nasiri, Mario Kahn, and Gina Butrico for their skilled technical assistance. This study was funded by grants from the US Public Health Service (R01 DK40936, R01 AG-23686, P30 DK059635). Kasper Faarkrog was supported with a Danish scholarship from Direktor Jacob Madsen og hustru Olga Madsens Fond.

- Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor- α . *J Clin Invest* 94:1543–1549.
- Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science* 259:87–91.
- Ozcan L, Tabas I (2016) Calcium signalling and ER stress in insulin resistance and atherosclerosis. *J Intern Med* 280:457–464.
- Samuel VT, Shulman GI (2012) Mechanisms for insulin resistance: Common threads and missing links. *Cell* 148:852–871.
- Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. *J Clin Invest* 126:12–22.
- Camporez JP, et al. (2013) Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. *Endocrinology* 154:1021–1028.

7. Jurczak MJ, et al. (2012) Dissociation of inositol-requiring enzyme (IRE1 α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. *J Biol Chem* 287:2558–2567.
8. Lee HY, et al. (2017) Mitochondrial-targeted catalase protects against high-fat diet-induced muscle insulin resistance by decreasing intramuscular lipid accumulation. *Diabetes* 66:2072–2081.
9. Shulman GI (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med* 371:1131–1141.
10. Holland WL, et al. (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. *Nat Med* 17:55–63.
11. Xia JY, et al. (2015) Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. *Cell Metab* 22:266–278.
12. Xia JY, Morley TS, Scherer PE (2014) The adipokine/ceramide axis: Key aspects of insulin sensitization. *Biochimie* 96:130–139.
13. Knowles JW, et al.; RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) Consortium; EUGENE2 (European Network on Functional Genomics of Type 2 Diabetes) Study; GUARDIAN (Genetics Underlying DIabetes in HispaNics) Consortium; SAPHIRE (Stanford Asian and Pacific Program for Hypertension and Insulin Resistance) Study (2015) Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. *J Clin Invest* 125:1739–1751.
14. Camporez JP, et al. (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. *Endocrinology* 154:3099–3109.
15. Camporez JP, et al. (2015) Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. *J Endocrinol* 226:207–217.
16. Camporez JP, et al. (2015) ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. *J Lipid Res* 56:526–536.
17. Samuel VT, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem* 279:32345–32353.
18. Samuel VT, et al. (2007) Inhibition of protein kinase C ϵ prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *J Clin Invest* 117:739–745.
19. Petersen MC, et al. (2016) Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. *J Clin Invest* 126:4361–4371.
20. Petersen KF, et al. (2003) Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. *Science* 300:1140–1142.
21. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N Engl J Med* 350:664–671.
22. Petersen KF, et al. (2015) Effect of aging on muscle mitochondrial substrate utilization in humans. *Proc Natl Acad Sci USA* 112:11330–11334.
23. Befroy DE, et al. (2007) Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. *Diabetes* 56:1376–1381.
24. Perry RJ, et al. (2015) Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. *Cell* 160:745–758.
25. Shulman GI (2000) Cellular mechanisms of insulin resistance. *J Clin Invest* 106:171–176.
26. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: Unravelling the mechanism. *Lancet* 375:2267–2277.
27. Lee HY, et al. (2010) Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. *Cell Metab* 12:668–674.
28. Choi CS, et al. (2007) Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. *J Clin Invest* 117:1995–2003.
29. Kim JK, et al. (2004) PKC- θ knockout mice are protected from fat-induced insulin resistance. *J Clin Invest* 114:823–827.
30. Yu C, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J Biol Chem* 277:50230–50236.
31. Kumashiro N, et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. *Proc Natl Acad Sci USA* 108:16381–16385.
32. Ter Horst KW, et al. (2017) Hepatic diacylglycerol-associated protein kinase C α translocation links hepatic steatosis to hepatic insulin resistance in humans. *Cell Rep* 19:1997–2004.
33. Szendroedi J, et al. (2014) Role of diacylglycerol activation of PKC θ in lipid-induced muscle insulin resistance in humans. *Proc Natl Acad Sci USA* 111:9597–9602.
34. Perry RJ, et al. (2013) Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. *Cell Metab* 18:740–748.
35. Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI (2015) Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. *Science* 347:1253–1256.
36. Chennamsetty I, et al. (2016) Nat1 deficiency is associated with mitochondrial dysfunction and exercise intolerance in mice. *Cell Rep* 17:527–540.
37. Tschöp MH, et al. (2011) A guide to analysis of mouse energy metabolism. *Nat Methods* 9:57–63.
38. Bonnard C, et al. (2008) Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. *J Clin Invest* 118:789–800.
39. Zhang D, et al. (2007) Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. *Proc Natl Acad Sci USA* 104:17075–17080.
40. Morino K, et al. (2005) Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. *J Clin Invest* 115:3587–3593.
41. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 226:497–509.